Details of the Drug

General Information of Drug (ID: DMCRQHB)

Drug Name
Edrophonium
Synonyms
EDR; Edrophonum; Edroponium; Reversol; Tensilon; EDROPHONIUM ION; Edrophone Chloride; Enlon Plus; ENLON-PLUS; Enlon (TN); Reversol (TN); Tensilon (TN); Ethyl-(3-hydroxyphenyl)-dimethylazanium; Ethyl-(3-hydroxy-phenyl)-dimethyl-ammonium; N-ethyl-3-hydroxy-N,N-dimethylanilinium; N-ethyl-3-hydroxy-N,N-dimethylbenzenaminium; (3-hydroxyphenyl)dimethylethylammonium; 3-hydroxy-N,N-dimethyl-N-ethylanilinium
Indication
Disease Entry ICD 11 Status REF
Myasthenia gravis 8C6Y Approved [1]
Therapeutic Class
Antidotes
Affected Organisms
Humans and other mammals
ATC Code
V04CX07: Edrophonium
V04CX: Other diagnostic agents
V04C: OTHER DIAGNOSTIC AGENTS
V04: DIAGNOSTIC AGENTS
V: VARIOUS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 166.24
Logarithm of the Partition Coefficient (xlogp) 1.8
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 1
ADMET Property
Absorption
The drug is rapidly absorbed []
Clearance
The drug present in the plasma can be removed from the body at the rate of 9.6 mL/min/kg [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 33 - 110 minutes [2]
Vd
The volume of distribution (Vd) of drug is 1.6 +/- 0.4 L/kg []
Chemical Identifiers
Formula
C10H16NO+
IUPAC Name
ethyl-(3-hydroxyphenyl)-dimethylazanium
Canonical SMILES
CC[N+](C)(C)C1=CC(=CC=C1)O
InChI
InChI=1S/C10H15NO/c1-4-11(2,3)9-6-5-7-10(12)8-9/h5-8H,4H2,1-3H3/p+1
InChIKey
VWLHWLSRQJQWRG-UHFFFAOYSA-O
Cross-matching ID
PubChem CID
3202
ChEBI ID
CHEBI:251408
CAS Number
312-48-1
UNII
70FP3JLY7N
DrugBank ID
DB01010
TTD ID
D0S5LH

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Acetylcholinesterase (AChE) TT1RS9F ACES_HUMAN Inhibitor [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Acetylcholinesterase (ACHE) OT2H8HG6 ACES_HUMAN Gene/Protein Processing [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Myasthenia gravis
ICD Disease Classification 8C6Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Acetylcholinesterase (AChE) DTT ACHE 6.39E-02 -1.07 -1.15
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Edrophonium
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Neostigmine DM6T2J3 Moderate Additive cholinergic effects by the combination of Edrophonium and Neostigmine. Myasthenia gravis [8C6Y] [5]
Coadministration of a Drug Treating the Disease Different from Edrophonium (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Bethanechol DMCLHO0 Moderate Additive cholinergic effects by the combination of Edrophonium and Bethanechol. Abnormal micturition [MF50] [5]
Mepenzolate DM8YU2F Moderate Antagonize the effect of Edrophonium when combined with Mepenzolate. Digestive system disease [DE2Z] [6]
Oxybutynine DMJPBAX Moderate Antagonize the effect of Edrophonium when combined with Oxybutynine. Discovery agent [N.A.] [6]
Solifenacin DMG592Q Moderate Antagonize the effect of Edrophonium when combined with Solifenacin. Functional bladder disorder [GC50] [6]
Tolterodine DMSHPW8 Moderate Antagonize the effect of Edrophonium when combined with Tolterodine. Functional bladder disorder [GC50] [6]
Belladonna DM2RBWK Moderate Antagonize the effect of Edrophonium when combined with Belladonna. Infectious gastroenteritis/colitis [1A40] [6]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Edrophonium and Thalidomide. Multiple myeloma [2A83] [7]
Siponimod DM2R86O Major Increased risk of atrioventricular block by the combination of Edrophonium and Siponimod. Multiple sclerosis [8A40] [7]
Fingolimod DM5JVAN Moderate Increased risk of bradycardia by the combination of Edrophonium and Fingolimod. Multiple sclerosis [8A40] [8]
Ozanimod DMT6AM2 Moderate Increased risk of atrioventricular block by the combination of Edrophonium and Ozanimod. Multiple sclerosis [8A40] [9]
Flavoxate DMKV4NL Moderate Antagonize the effect of Edrophonium when combined with Flavoxate. Pain [MG30-MG3Z] [6]
Methylscopolamine DM5VWOB Moderate Antagonize the effect of Edrophonium when combined with Methylscopolamine. Peptic ulcer [DA61] [6]
Procainamide DMNMXR8 Moderate Antagonize the effect of Edrophonium when combined with Procainamide. Ventricular tachyarrhythmia [BC71] [6]
⏷ Show the Full List of 13 DDI Information of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040131.
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
4 Effect of reversible ligands on oxime-induced reactivation of sarin- and cyclosarin-inhibited human acetylcholinesterase. Toxicol Lett. 2015 Feb 3;232(3):557-65.
5 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
6 Product Information. Mestinon (pyridostigmine). ICN Pharmaceuticals Inc, Cost Mesa, CA.
7 Cerner Multum, Inc. "Australian Product Information.".
8 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
9 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.